Puma Biotechnology, Inc. — 2013 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2013. The company is a development-stage biopharmaceutical business focused on oncology; it had no approved products or product revenue during the year.
Business context and pipeline
Puma’s lead candidate is oral neratinib (PB272), licensed from Pfizer, which it is developing across HER2-positive breast cancer, HER2-mutated non-small cell lung cancer, and other HER2-mutated solid tumors. Its other licensed candidates are intravenous neratinib and PB357. The company depends on clinical development, third-party research organizations and manufacturers, and external financing.
Key financial metrics
| Metric | 2013 | 2012 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $45.0 million | $49.6 million |
| General and administrative expense | $9.8 million | $24.8 million |
| Operating loss | $54.8 million | $74.5 million |
| Net loss | $54.7 million | $74.4 million |
| Basic and diluted loss per share | $1.90 | $3.42 |
| Cash used in operating activities | $55.0 million | $44.0 million |
At December 31, 2013, cash and cash equivalents were $43.0 million and marketable securities were $40.9 million; total current assets were $96.4 million, current liabilities $19.3 million, total liabilities $20.4 million, and stockholders’ equity $84.0 million. No material debt balance is reported in the supplied filing text. The company reported no product-sales margins; margin measures are not meaningful for its pre-commercial stage.
Changes versus 2012
- Net loss narrowed by about $19.7 million, mainly because 2012 included $18.2 million of expense from revaluing the CEO’s anti-dilutive warrant; the company said this expense was fully recorded and was not expected to recur.
- R&D expense fell about 9%, reflecting the cap on Puma’s responsibility for certain Pfizer legacy-trial costs and increased spending on company-sponsored trials. R&D spending is expected to rise as development advances.
- Cash used in operations increased by about $11.0 million despite the lower net loss. Cash and cash equivalents declined by $94.4 million during 2013, while the company invested in marketable securities.
Outlook, commentary, and risks
- Management estimated next-12-month R&D spending of $50–$60 million, excluding stock-based compensation, and G&A spending of $7–$8 million, excluding stock-based compensation. It expected year-end 2013 resources, together with subsequent financing, to fund operations through 2015 and beyond.
- On February 14, 2014, after year-end, Puma raised approximately $129.3 million net from a common-stock offering. This is a subsequent event, not 2013 operating cash flow.
- The Phase III trial of neratinib plus capecitabine versus lapatinib plus capecitabine in third-line HER2-positive metastatic breast cancer began enrolling in 2013. It was designed for approximately 600 patients, with progression-free survival and overall survival as co-primary endpoints. FDA agreement under a Special Protocol Assessment does not assure approval.
- Management reported that the neratinib regimen graduated from the adaptive I-SPY 2 trial for a HER2-positive/hormone-receptor-negative signature; the reported Bayesian predictive probability of success in a confirmatory Phase III trial was 78.1%. These findings are not equivalent to confirmatory Phase III results.
- Principal risks include clinical-trial failure or delay, safety and tolerability (notably diarrhea), regulatory uncertainty, reliance on Pfizer-licensed intellectual property, third-party CROs and manufacturers, competition, and the need for future capital. The Pfizer license carries potential milestone payments totaling up to $187.5 million and royalties of approximately 10%–20% of net sales if products are commercialized.
- The company reported effective disclosure controls and internal control over financial reporting, with an unqualified auditor opinion. It disclosed no material pending legal proceedings.
Important facts for investors to verify
- Clinical-trial enrollment, protocol adherence, safety findings, and subsequent efficacy data for the Phase III breast-cancer trial and other neratinib studies.
- Whether management’s stated cash runway and spending estimates remain valid, including the effect of the February 2014 offering and ongoing trial costs.
- Terms and potential timing of Pfizer milestone obligations, royalty rates, and reimbursement of capped legacy-trial expenses.
- Future dilution, including outstanding options and the CEO warrant for 2,116,250 shares exercisable at $16 per share through October 2021.
- Whether the I-SPY 2 findings are confirmed in later trials and whether regulatory agencies accept the evidence and proposed endpoints.